Heart surgery is done to correct problems with the heart. More than half a million heart surgeries are done each year in the United States for a variety of heart problems. Heart surgery is used to correct heart problems in children and adults. This article discusses heart surgeries for adults. For more information about heart surgeries for children, see the Diseases and Conditions Index articles on congenital heart defects, holes in the heart, and tetralogy of Fallot.
The most common type of heart surgery for adults is coronary artery bypass grafting (CABG). During CABG, surgeons use healthy arteries or veins taken from another part of the body to bypass (that is, go around) blocked arteries. CABG relieves chest pain and reduces the risk of heart attack.
Building on the success of previous efforts among researchers and caregivers to improve the care of chronically ill children, a $12-million grant to Cincinnati Children's Hospital Medical Center will allow creation of a registry system unlike any before it, providing information in real time on thousands of cases around the country – and eventually the world.
A research team from the University of British Columbia and the Child & Family Research Institute (CFRI) at BC Children's Hospital has identified the role of a type of T cell in type 1 diabetes that may lead to new treatment options for young patients.
A century-old posture improvement technique developed by Shakespearian actor F.M. Alexander to correct his chronic laryngitis appears to enhance the posture and proficiency of surgeons who perform minimally invasive procedures.
Physicians have identified a risk factor for heart disease in adulthood that can be present in children as young as 10. They're also calling for screening for this risk factor to help motivate children to exercise and lose weight.
The New York State Hospital Review and Planning Council today approved North Shore-LIJ Health System's request to extend its open-heart surgery program to Southside Hospital in Bay Shore, bringing one of New York's most renowned cardiothoracic surgery programs to Suffolk County's south shore. The council's action will be forwarded to State Health Commissioner Richard Daines, MD, for final approval.
The Washington Post: "Back in Iowa, President Obama got an earful Wednesday from voters about two of his key policies: health care, and his desire to roll back Bush-era tax cuts. ... Standing in the back yard of a resident, Obama stood patiently as one woman described, at length, her fears that the U.S. health-care system will soon resemble that of Great Britain. ... The official topic in Iowa was 'challenges currently facing the middle class,' part of a series of similar economy-driven stops" (Kornblut, 9/29).
St. Jude Medical, Inc., a global medical device company, today announced that physicians from the Cedars-Sinai Heart Institute will lead the company's transcatheter aortic valve implantation (TAVI) clinical trial. The study will evaluate the safety and efficacy of the St. Jude Medical transcatheter aortic valve for patients who experience severe aortic stenosis and who may be at an elevated risk for open-heart surgery.
Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates.
NewYork-Presbyterian Hospital/Columbia University Medical Center today announced the opening of The Carmen and John Thain Center for Prenatal Pediatrics. The new unit will provide high-risk pregnant women and their babies the most comprehensive care currently available, all in one location.
Just released data from a clinical trial shows promise for a new minimally invasive treatment option for patients with severe aortic stenosis who are too sick for traditional forms of open-heart surgery. As compared to standard medical therapy, the new procedure, transcatheter aortic valve implantation (TAVI), significantly reduced mortality rates in patients who received the new valve.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced enrollment of the first patient in the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) trial which is designed to assess patient outcomes using a standardized, best practices approach in endoscopic vessel harvesting (EVH) for coronary artery bypass graft surgery (CABG) compared with open vein harvesting methods.
Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives, according to a new multicenter study, to be published online at 2 p.m. Pacific time today in the New England Journal of Medicine.
While aging impacts everyday living in many ways, the latest technologies in the medical, consumer and lifestyle fields have the potential to help older adults live better for longer.
The Virginia Commonwealth University Medical Center is the lead institution in a national clinical trial of technology that will allow artificial heart patients to recuperate, rehabilitate and wait in the comfort of their own homes until a donor heart becomes available for transplant.
Using a newly FDA approved pulmonary valve, Dr. Frank Ing, director of the catheterization laboratory at Texas Children's Hospital and his team of pediatric interventional cardiologists implanted a transcatheter pulmonary heart valve into the heart of a 13-year-old girl, which spared her from having her chest opened for a third heart surgery.
Medtronic, Inc. today announced CE Mark approval and the first global use and launch of the Medtronic CoreValve® delivery system with AccuTrak™ Stability Layer for transcatheter aortic valve implantation (TAVI). AccuTrak's proprietary technology allows physicians to achieve enhanced control and accuracy in the deployment of the CoreValve device.
The European Society of Cardiology (ESC) today announces the release of new Clinical Practice Guidelines covering the management of Grown-up Congenital Heart Disease (GUCH). More than two million adults in Europe are assumed to be affected by the condition, and the numbers are growing as a consequence of sharply increased survival rates due to advances in paediatric cardiology and heart surgery.
Scientists have identified a genetic basis for determining the severity of allergic asthma in experimental models of the disease.The study may help in the search for future therapeutic strategies to fight a growing medical problem that currently lacks effective treatments, researchers from Cincinnati Children's Hospital Medical Center report in the Aug. 29 Nature Immunology.
When Doris Snyder celebrated her 102nd birthday on August 10, she was that much closer to the expected birth of her first great-granddaughter who's due to arrive early September. She is very excited about the milestone, which might not have been possible were it not for a cutting-edge, experimental procedure that replaced one of Doris' heart valves weeks earlier when she was 101. The valve had been rendered useless by aortic valve stenosis—hardening from calcium deposits that restrict the flow of blood from the heart.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.